Lexeo Therapeutics Return on Equity (ROE) Growth & History (LXEO)
Lexeo Therapeutics's return on equity was −55.00% for fiscal 2025.
View full Lexeo Therapeutics company overviewLexeo Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −55.00% | +30.37 pp |
| 2024 | 2024-12-31 | −85.37% | +22769.71 pp |
| 2023 | 2023-12-31 | −22,855.08% | — |
Lexeo Therapeutics quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −11.09% | +11.98 pp |
| Q1 2026 | 2026-03-31 | −8.45% | +23.42 pp |
| Q4 2025 | 2025-12-31 | −11.38% | +8.86 pp |
| Q3 2025 | 2025-09-30 | −15.66% | +3.72 pp |
| Q2 2025 | 2025-06-30 | −23.07% | −10.86 pp |
| Q1 2025 | 2025-03-31 | −31.87% | −17.24 pp |
| Q4 2024 | 2024-12-31 | −20.24% | — |
| Q3 2024 | 2024-09-30 | −19.38% | — |
| Q2 2024 | 2024-06-30 | −12.21% | — |
| Q1 2024 | 2024-03-31 | −14.63% | — |
Lexeo Therapeutics return on equity trends
Between the periods ended 2023-12-31 and 2025-12-31, Lexeo Therapeutics's return on equity increased from −22,855.08% to −55.00%, a change of +22800.08 percentage points. The latest reported quarter, Q2 2026, shows −11.09%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lexeo Therapeutics source filings ↗